vs
FTAI Aviation Ltd.（FTAI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
FTAI Aviation Ltd.的季度营收约是Royalty Pharma plc的1.3倍（$830.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 16.2%，领先18.3%），FTAI Aviation Ltd.同比增速更快（65.5% vs 4.8%），过去两年FTAI Aviation Ltd.的营收复合增速更高（36.8% vs 4.6%）
FTAI航空有限公司是一家全球性航空基础设施及解决方案提供商，主营商用飞机、航空发动机及相关航空资产的持有、租赁与维护业务，为全球商用航空公司、货运运营商提供定制化资产管理及售后支持服务，助力客户提升运营效率。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FTAI vs RPRX — 直观对比
营收规模更大
FTAI
是对方的1.3倍
$622.0M
营收增速更快
FTAI
高出60.7%
4.8%
净利率更高
RPRX
高出18.3%
16.2%
两年增速更快
FTAI
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $830.7M | $622.0M |
| 净利润 | $134.2M | $214.2M |
| 毛利率 | 36.9% | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 16.2% | 34.4% |
| 营收同比 | 65.5% | 4.8% |
| 净利润同比 | 34.7% | 2.9% |
| 每股收益（稀释后） | $1.29 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTAIRPRX
| Q1 26 | $830.7M | — | ||
| Q4 25 | $662.0M | $622.0M | ||
| Q3 25 | $667.1M | $609.3M | ||
| Q2 25 | $676.2M | $578.7M | ||
| Q1 25 | $502.1M | $568.2M | ||
| Q4 24 | $498.8M | $593.6M | ||
| Q3 24 | $465.8M | $564.7M | ||
| Q2 24 | $443.6M | $537.3M |
净利润FTAIRPRX
| Q1 26 | $134.2M | — | ||
| Q4 25 | $115.6M | $214.2M | ||
| Q3 25 | $117.7M | $288.2M | ||
| Q2 25 | $165.4M | $30.2M | ||
| Q1 25 | $102.4M | $238.3M | ||
| Q4 24 | $102.4M | $208.2M | ||
| Q3 24 | $86.5M | $544.0M | ||
| Q2 24 | $-219.9M | $102.0M |
毛利率FTAIRPRX
| Q1 26 | 36.9% | — | ||
| Q4 25 | 44.3% | — | ||
| Q3 25 | 45.6% | — | ||
| Q2 25 | 45.4% | — | ||
| Q1 25 | 50.5% | — | ||
| Q4 24 | 48.3% | — | ||
| Q3 24 | 52.9% | — | ||
| Q2 24 | 53.6% | — |
营业利润率FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 20.3% | 62.4% | ||
| Q3 25 | 21.6% | 70.1% | ||
| Q2 25 | 30.1% | 36.3% | ||
| Q1 25 | 24.9% | 94.0% | ||
| Q4 24 | 21.7% | 60.9% | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | -52.5% | 50.2% |
净利率FTAIRPRX
| Q1 26 | 16.2% | — | ||
| Q4 25 | 17.5% | 34.4% | ||
| Q3 25 | 17.6% | 47.3% | ||
| Q2 25 | 24.5% | 5.2% | ||
| Q1 25 | 20.4% | 41.9% | ||
| Q4 24 | 20.5% | 35.1% | ||
| Q3 24 | 18.6% | 96.3% | ||
| Q2 24 | -49.6% | 19.0% |
每股收益（稀释后）FTAIRPRX
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.06 | $0.49 | ||
| Q3 25 | $1.10 | $0.67 | ||
| Q2 25 | $1.57 | $0.07 | ||
| Q1 25 | $0.87 | $0.55 | ||
| Q4 24 | $0.87 | $0.46 | ||
| Q3 24 | $0.76 | $1.21 | ||
| Q2 24 | $-2.26 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $412.2M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $431.7M | $9.7B |
| 总资产 | $4.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FTAIRPRX
| Q1 26 | $412.2M | — | ||
| Q4 25 | $300.5M | $618.7M | ||
| Q3 25 | $509.9M | $938.9M | ||
| Q2 25 | $301.9M | $631.9M | ||
| Q1 25 | $112.1M | $1.1B | ||
| Q4 24 | $115.1M | $929.0M | ||
| Q3 24 | $111.9M | $950.1M | ||
| Q2 24 | $169.5M | $1.8B |
总债务FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $3.4B | $9.0B | ||
| Q3 25 | $3.4B | $8.9B | ||
| Q2 25 | $3.4B | $8.0B | ||
| Q1 25 | $3.6B | $7.6B | ||
| Q4 24 | $3.4B | $7.6B | ||
| Q3 24 | $3.2B | $7.6B | ||
| Q2 24 | $3.1B | $7.6B |
股东权益FTAIRPRX
| Q1 26 | $431.7M | — | ||
| Q4 25 | $334.2M | $9.7B | ||
| Q3 25 | $252.5M | $9.6B | ||
| Q2 25 | $164.9M | $9.5B | ||
| Q1 25 | $28.3M | $9.8B | ||
| Q4 24 | $81.4M | $10.3B | ||
| Q3 24 | $118.5M | $10.3B | ||
| Q2 24 | $69.6M | $9.8B |
总资产FTAIRPRX
| Q1 26 | $4.5B | — | ||
| Q4 25 | $4.4B | $19.6B | ||
| Q3 25 | $4.2B | $19.3B | ||
| Q2 25 | $4.1B | $18.3B | ||
| Q1 25 | $4.3B | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $3.7B | $18.0B | ||
| Q2 24 | $3.4B | $17.7B |
负债/权益比FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 10.32× | 0.92× | ||
| Q3 25 | 13.65× | 0.93× | ||
| Q2 25 | 20.88× | 0.84× | ||
| Q1 25 | 128.56× | 0.78× | ||
| Q4 24 | 42.28× | 0.74× | ||
| Q3 24 | 27.15× | 0.74× | ||
| Q2 24 | 44.24× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $-179.1M | $827.1M | ||
| Q3 25 | $4.6M | $702.6M | ||
| Q2 25 | $-110.3M | $364.0M | ||
| Q1 25 | $-26.0M | $596.1M | ||
| Q4 24 | $-41.8M | $742.5M | ||
| Q3 24 | $41.5M | $703.6M | ||
| Q2 24 | $-187.3M | $658.2M |
自由现金流FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $-189.3M | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-117.2M | — | ||
| Q1 25 | $-30.1M | — | ||
| Q4 24 | $-48.1M | — | ||
| Q3 24 | $41.0M | — | ||
| Q2 24 | $-188.4M | — |
自由现金流率FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | -28.6% | — | ||
| Q3 25 | -0.3% | — | ||
| Q2 25 | -17.3% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | -9.6% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | -42.5% | — |
资本支出强度FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.3% | — |
现金转化率FTAIRPRX
| Q1 26 | — | — | ||
| Q4 25 | -1.55× | 3.86× | ||
| Q3 25 | 0.04× | 2.44× | ||
| Q2 25 | -0.67× | 12.06× | ||
| Q1 25 | -0.25× | 2.50× | ||
| Q4 24 | -0.41× | 3.57× | ||
| Q3 24 | 0.48× | 1.29× | ||
| Q2 24 | — | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTAI
| Aerospace products revenue | $522.6M | 63% |
| MRE Contract revenue | $221.2M | 27% |
| Lease income | $39.9M | 5% |
| Maintenance revenue | $30.6M | 4% |
| Asset sales revenue | $10.2M | 1% |
| Other revenue (1) | $6.2M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
